Quality of life in patients with allergic rhinitis

被引:154
作者
Thompson, AK
Juniper, E
Meltzer, EO
机构
[1] Aventis Pharmaceut Inc, US Med Affairs, Kansas City, MO 64137 USA
[2] McMaster Univ, Hamilton, ON, Canada
[3] Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA
关键词
D O I
10.1016/S1081-1206(10)62543-4
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Learning objectives: Reading this article will familiarize the practitioner with ongoing efforts to measure the effects of allergic rhinitis symptoms and its treatments on the health-related quality of life (HRQOL) of patients. The reader will learn about instruments used to collect HRQOL data, results of studies showing the burden of illness and the effects of treatments on HRQOL, and efforts to interpret the clinical relevance of changes in HRQOL status. Data sources: Information was gleaned from articles listed in MEDLINE regarding HRQOL in allergic rhinitis between 1966 and 2000 (English language only), and from the personal experiences of the authors. Study selection: Questionnaire validation studies and representative controlled trials employing measures to assess the effects of allergic rhinitis symptoms and its treatments on HRQOL are described. Results from this Review: Allergic rhinitis symptoms can have detrimental effects on the physical, psychologic, and social aspects of patients' lives. Clinical trial data suggest a variety of pharmacologic therapies can significantly improve HRQOL in patients with allergic rhinitis. Validated questionnaires are now available that can easily be used in clinical practice to measure the effects of interventions on HRQOL for individual patients. Conclusions: Evaluating the effects of interventions on HRQOL may be particularly important in a non-life-threatening condition such as rhinitis. Health-related quality of life measures can be used to indicate the risk/benefit and the cost/benefit ratios of competing treatment options. Clinicians and policy makers are already using HRQOL data to evaluate results of medical interventions to guide patient management and reimbursement decisions.
引用
收藏
页码:338 / +
页数:8
相关论文
共 39 条
[1]  
BLAISS MS, 1995, ANN ALLERG ASTHMA IM, V74, P359
[2]   Quality of life in allergic rhinitis [J].
Blaiss, MS .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 83 (05) :449-454
[3]   Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire [J].
Bousquet, J ;
Duchateau, J ;
Pignat, JC ;
Marquis, P ;
Mariz, S ;
Ware, JE ;
Valentin, B ;
Burtin, B .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 98 (02) :309-316
[4]  
Caro JJ, 1999, AM J RESP CRIT CARE, V159, pA693
[5]  
Chatellier G, 1996, BRIT MED J, V312, P426
[6]   The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis [J].
deGraafintVeld, T ;
Koenders, S ;
Garrelds, IM ;
vanWijk, RG .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 98 (03) :508-513
[7]   Impact on quality of life during an allergen challenge research trial [J].
Ellis, AK ;
Day, JH ;
Lundie, MJ .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 83 (01) :33-39
[8]  
Goodwin B, 1997, J ALLERGY CLIN IMMUN, V99, P1100
[9]   MEASURING HEALTH-RELATED QUALITY-OF-LIFE [J].
GUYATT, GH ;
FEENY, DH ;
PATRICK, DL .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (08) :622-629
[10]   MEASUREMENT OF HEALTH-STATUS - ASCERTAINING THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE [J].
JAESCHKE, R ;
SINGER, J ;
GUYATT, GH .
CONTROLLED CLINICAL TRIALS, 1989, 10 (04) :407-415